This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ferreri, A. J.M. Articles by Cavalli, F. Search for Related Content PubMed PubMed Citation Articles by Ferreri, A. J.M. Articles by Cavalli, F. Social Bookmarking                            What's this?

Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience

Andrés J.M. Ferreri, Jean-Yves Blay, Michele Reni, Felice Pasini, Michele Spina, Achille Ambrosetti, Antonello Calderoni, Andrea Rossi, Vittorio Vavassori, Annarita Conconi, Liliana Devizzi, Françoise Berger, Maurilio Ponzoni, Bettina Borisch, Marianne Tinguely, Michele Cerati, Mario Milani, Enrico Orvieto, Juvenal Sanchez, Christine Chevreau, Stefania Dell’Oro, Emanuele Zucca, Franco Cavalli

From the Departments of Radiochemotherapy and Pathology, San Raffaele H Scientific Institute, and Divisione di Oncologia Medica, Istituto Nazionale dei Tumori, Milan; Divisione di Radioterapia, Ospedale di Circolo e Fondazione Macchi, and Anatomia e Istologia Patologica, Ospedale di Circolo Fondazione Macchi, Università dell’Insubria, Varese; Divisione Clinicizzata di Oncologia Medica, Ospedale Civile Maggiore, and Cattedra di Ematologia, Università di Verona, Ospedale Policlinico di Borgo Roma, Verona; Division of Medical Oncology "A," Centro di Riferimento Oncologico, National Cancer Institute, Aviano; Divisione di Ematologia, Ospedali Riuniti di Bergamo, Bergamo; Divisione di Anatomia Patologica, Azienda Ospedaliera di Lecco, Lecco; Istituto di Anatomia e Istologia Patologica, Ospedale Regionale di Treviso, Treviso, Italy; Unité Cytokines et Cancers, Hopital E. Herriot & Centre Léon Bérard, and Service de Pathologie, Centre Hospitalier Lyon-Sud, Lyon; Centre Claudius Regaud, Toulouse, France; Istituto Oncologico della Svizzera Italiana, Ospedale San Giovannia, Bellinzona; Institut für Medizinische Onkologie Inselspital, Bern; Division de Pathologie Clinique, Hôpitaux Universitaires de Genève, Hôpital Cantonal, Genève, Switzerland; and Departamento de Anatomia Patológica, Instituto de Enfermedades Neoplásicas, Lima, Perú.

Address reprint requests to Andrés J.M. Ferreri, MD, Department of Radiochemotherapy, San Raffaele H Scientific Institute, via Olgettina 60, 20132, Milan, Italy; email: andres.ferreri{at}hsr.it.

Purpose: To identify survival predictors and to design a prognostic score useful for distinguishing risk groups in immunocompetent patients with primary CNS lymphomas (PCNSL).

Patients and Methods: The prognostic role of patient-, lymphoma-, and treatment-related variables was analyzed in a multicenter series of 378 PCNSL patients treated at 23 cancer centers from five different countries.

Results: Age more than 60 years, performance status (PS) more than 1, elevated lactate dehydrogenase (LDH) serum level, high CSF protein concentration, and involvement of deep regions of the brain (periventricular regions, basal ganglia, brainstem, and/or cerebellum) were significantly and independently associated with a worse survival. These five variables were used to design a prognostic score. Each variable was assigned a value of either 0, if favorable, or 1, if unfavorable. The values were then added together to arrive at a final score, which was tested in 105 assessable patients for which complete data of all five variables were available. The 2-year overall survival (OS) ± SD was 80% ± 8%, 48% ± 7%, and 15% ± 7% (P = .00001) for patients with zero to one, two to three, and four to five unfavorable features, respectively. The prognostic role of this score was confirmed by limiting analysis to assessable patients treated with high-dose methotrexate-based chemotherapy (2-year OS ± SD: 85% ± 8%, 57% ± 8%, and 24% ± 11%; P = .0004).

Conclusion: Age, PS, LDH serum level, CSF protein concentration, and involvement of deep structures of the brain were independent predictors of survival. A prognostic score including these five parameters seems advisable in distinguishing different risk groups in PCNSL patients. The proposed score and its relevance in therapeutic decision deserve to be validated in further studies.

Presented at the Forty-Second Annual Meeting of the American Society of Hematology, December 6–10, San Francisco, CA, 2000

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Sierra del Rio, A. Rousseau, C. Soussain, D. Ricard, and K. Hoang-Xuan Primary CNS Lymphoma in Immunocompetent Patients Oncologist, May 1, 2009; 14(5): 526 - 539. [Abstract] [Full Text] [PDF]

				I.S. Haldorsen, J. Krakenes, B.K. Krossnes, O. Mella, and A. Espeland CT and MR Imaging Features of Primary Central Nervous System Lymphoma in Norway, 1989-2003 AJNR Am. J. Neuroradiol., April 1, 2009; 30(4): 744 - 751. [Abstract] [Full Text] [PDF]

				G. Illerhaus, R. Marks, F. Muller, G. Ihorst, F. Feuerhake, M. Deckert, C. Ostertag, and J. Finke High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study Ann. Onc., February 1, 2009; 20(2): 319 - 325. [Abstract] [Full Text] [PDF]

				J.-J. Zhu, E. R. Gerstner, D. A. Engler, M. M. Mrugala, W. Nugent, K. Nierenberg, F. H. Hochberg, R. A. Betensky, and T. T. Batchelor High-dose methotrexate for elderly patients with primary CNS lymphoma Neuro-oncol, January 1, 2009; 11(2): 211 - 215. [Abstract] [Full Text] [PDF]

				J.-F. Mineo, A. Scheffer, C. Karkoutly, L. Nouvel, O. Kerdraon, J. Trauet, A. Bordron, J.-P. Dessaint, M. Labalette, C. Berthou, et al. Using Human CD20-Transfected Murine Lymphomatous B Cells to Evaluate the Efficacy of Intravitreal and Intracerebral Rituximab Injections in Mice Invest. Ophthalmol. Vis. Sci., November 1, 2008; 49(11): 4738 - 4745. [Abstract] [Full Text] [PDF]

				F. M. Cady, B. P. O'Neill, M. E. Law, P. A. Decker, D. M. Kurtz, C. Giannini, A. B. Porter, P. J. Kurtin, P. B. Johnston, A. Dogan, et al. Del(6)(q22) and BCL6 Rearrangements in Primary CNS Lymphoma Are Indicators of an Aggressive Clinical Course J. Clin. Oncol., October 10, 2008; 26(29): 4814 - 4819. [Abstract] [Full Text] [PDF]

				L. Fischer, P. Martus, M. Weller, H. A. Klasen, B. Rohden, A. Roth, B. Storek, M. Hummel, T. Nagele, E. Thiel, et al. Meningeal dissemination in primary CNS lymphoma: Prospective evaluation of 282 patients Neurology, September 30, 2008; 71(14): 1102 - 1108. [Abstract] [Full Text] [PDF]

				Y. Shibamoto, H. Ogino, G. Suzuki, M. Takemoto, N. Araki, K. Isobe, E. Tsuchida, K. Nakamura, M. Kenjo, K. Suzuki, et al. Primary central nervous system lymphoma in Japan: Changes in clinical features, treatment, and prognosis during 1985-2004 Neuro-oncol, August 1, 2008; 10(4): 560 - 568. [Abstract] [Full Text] [PDF]

				N. D. Doolittle, L. E. Abrey, T. N. Shenkier, S. Tali, J. E.C. Bromberg, E. A. Neuwelt, C. Soussain, K. Jahnke, P. Johnston, G. Illerhaus, et al. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report Blood, February 1, 2008; 111(3): 1085 - 1093. [Abstract] [Full Text] [PDF]

				S. Roy, S. A. Josephson, J. Fridlyand, J. Karch, C. Kadoch, J. Karrim, L. Damon, P. Treseler, S. Kunwar, M. A. Shuman, et al. Protein Biomarker Identification in the CSF of Patients With CNS Lymphoma J. Clin. Oncol., January 1, 2008; 26(1): 96 - 105. [Abstract] [Full Text] [PDF]

				G. Illerhaus, F. Muller, F. Feuerhake, A.-O. Schafer, C. Ostertag, and J. Finke High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system Haematologica, January 1, 2008; 93(1): 147 - 148. [Abstract] [Full Text] [PDF]

				A. J. M. Ferreri, M. Reni, E. Zucca, and F. Cavalli Primary CNS Lymphomas Prognosis J. Clin. Oncol., September 20, 2007; 25(27): 4322 - 4324. [Full Text] [PDF]

				L. E. Abrey, L. Ben-Porat, K. S. Panageas, J. Yahalom, W. Curran, C. Schultz, S. Leibel, D. Nelson, M. Mehta, and L. M. DeAngelis In Reply J. Clin. Oncol., September 20, 2007; 25(27): 4324 - 4325. [Full Text] [PDF]

				M Montemurro, T Kiefer, F Schuler, H. Al-Ali, H-H Wolf, R Herbst, A Haas, K Helke, A Theilig, C Lotze, et al. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study Ann. Onc., April 1, 2007; 18(4): 665 - 671. [Abstract] [Full Text] [PDF]

				L. E. Abrey, L. Ben-Porat, K. S. Panageas, J. Yahalom, B. Berkey, W. Curran, C. Schultz, S. Leibel, D. Nelson, M. Mehta, et al. Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model J. Clin. Oncol., December 20, 2006; 24(36): 5711 - 5715. [Abstract] [Full Text] [PDF]

				I. T. Gavrilovic, A. Hormigo, J. Yahalom, L. M. DeAngelis, and L. E. Abrey Long-Term Follow-Up of High-Dose Methotrexate-Based Therapy With and Without Whole Brain Irradiation for Newly Diagnosed Primary CNS Lymphoma J. Clin. Oncol., October 1, 2006; 24(28): 4570 - 4574. [Abstract] [Full Text] [PDF]

				L. Fischer, E. Thiel, H.-A. Klasen, J. Birkmann, K. Jahnke, P. Martus, and A. Korfel Prospective trial on topotecan salvage therapy in primary CNS lymphoma Ann. Onc., July 1, 2006; 17(7): 1141 - 1145. [Abstract] [Full Text] [PDF]

				A.J.M. Ferreri, S. Dell'Oro, M. Foppoli, M. Bernardi, A. A. Brandes, A. Tosoni, M. Montanari, M. Balzarotti, M. Spina, F. Ilariucci, et al. MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas Neurology, May 9, 2006; 66(9): 1435 - 1438. [Abstract] [Full Text] [PDF]

				T. Batchelor and J. S. Loeffler Primary CNS Lymphoma J. Clin. Oncol., March 10, 2006; 24(8): 1281 - 1288. [Abstract] [Full Text] [PDF]

				C. S. Ha, L. J. Medeiros, C. Charnsangavej, M. Crump, and M. K. Gospodarowicz Oncodiagnosis Panel: 2004: Lymphoma RadioGraphics, March 1, 2006; 26(2): 607 - 620. [Full Text] [PDF]

				L. M. DeAngelis and F. M. Iwamoto An Update on Therapy of Primary Central Nervous System Lymphoma Hematology, January 1, 2006; 2006(1): 311 - 316. [Abstract] [Full Text] [PDF]

				L. E. Abrey, T. T. Batchelor, A. J.M. Ferreri, M. Gospodarowicz, E. J. Pulczynski, E. Zucca, J. R. Smith, A. Korfel, C. Soussain, L. M. DeAngelis, et al. Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma J. Clin. Oncol., August 1, 2005; 23(22): 5034 - 5043. [Abstract] [Full Text] [PDF]

				T. N. Shenkier, J.-Y. Blay, B. P. O'Neill, P. Poortmans, E. Thiel, K. Jahnke, L. E. Abrey, E. Neuwelt, R. Tsang, T. Batchelor, et al. Primary CNS Lymphoma of T-Cell Origin: A Descriptive Analysis From the International Primary CNS Lymphoma Collaborative Group J. Clin. Oncol., April 1, 2005; 23(10): 2233 - 2239. [Abstract] [Full Text] [PDF]

				P. L. Nguyen, A. Chakravarti, D. M. Finkelstein, F. H. Hochberg, T. T. Batchelor, and J. S. Loeffler Results of Whole-Brain Radiation As Salvage of Methotrexate Failure for Immunocompetent Patients With Primary CNS Lymphoma J. Clin. Oncol., March 1, 2005; 23(7): 1507 - 1513. [Abstract] [Full Text] [PDF]

				K. Jahnke, A. Korfel, P. Martus, M. Weller, U. Herrlinger, A. Schmittel, L. Fischer, E. Thiel, and On behalf of the German Primary Central Nervous Sy High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma Ann. Onc., March 1, 2005; 16(3): 445 - 449. [Abstract] [Full Text] [PDF]

				T. T. Batchelor, B. R. Buchbinder, and N. L. Harris Case 1-2005 - A 35-Year-Old Woman with Difficulty Walking, Headache, and Nausea N. Engl. J. Med., January 13, 2005; 352(2): 185 - 194. [Full Text] [PDF]

				L. Fischer, E. Thiel, H. A. Klasen, H. Kirchen, K. Jahnke, and A. Korfel Response of relapsed or refractory primary central nervous system lymphoma (PCNSL) to topotecan Neurology, May 25, 2004; 62(10): 1885 - 1887. [Abstract] [Full Text] [PDF]

				P. M.P. Poortmans, H. C. Kluin-Nelemans, H. Haaxma-Reiche, M. Van't Veer, M. Hansen, P. Soubeyran, M. Taphoorn, J. Thomas, M. Van den Bent, M. Fickers, et al. High-Dose Methotrexate-Based Chemotherapy Followed by Consolidating Radiotherapy in Non-AIDS-Related Primary Central Nervous System Lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962 J. Clin. Oncol., December 15, 2003; 21(24): 4483 - 4488. [Abstract] [Full Text] [PDF]

				A. J.M. Ferreri, L. E. Abrey, J.-Y. Blay, B. Borisch, J. Hochman, E. A. Neuwelt, J. Yahalom, E. Zucca, F. Cavalli, J. Armitage, et al. Summary Statement on Primary Central Nervous System Lymphomas From the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002 J. Clin. Oncol., June 15, 2003; 21(12): 2407 - 2414. [Abstract] [Full Text] [PDF]